PQS Phoqus

RNS Number:6805C
Phoqus Group plc
23 August 2007



 Notice of EGM to change name of Phoqus Group plc to Phoqus Pharmaceuticals plc


West Malling, UK, 23 August 2007: Phoqus Group plc (AIM: PQS) ("Phoqus" or
"Company"), the specialty pharmaceuticals drug development company, today
announces that it has convened an extraordinary general meeting ("EGM") of the
Company to approve the Board's proposal to change the Company's name to Phoqus
Pharmaceuticals plc.

In July 2007, the Company successfully concluded a Placing raising #5.2 million
to fund its new strategy as a specialty pharmaceutical drug development company
focused on the development of new therapeutic products for patients with
significant unmet medical needs. The net proceeds of the Placing will allow the
Company to continue the development of its lead product Chronocort(TM), with a
view to maximising value for shareholders.

In order to reflect this new strategy, the Board has decided that it is
appropriate to change the name of the Company from Phoqus Group plc to Phoqus
Pharmaceuticals plc. A notice has been sent to shareholders today convening an
EGM at the Company's registered office at 10:30 am on 18 September 2007 at which
the proposal to change the Company's name will be put to shareholders.

The proposed new name is currently used by the Company's trading subsidiary,
Phoqus Pharmaceuticals Ltd, and is already in daily use as a trading name of the
subsidiary, for example on the website. The name of the subsidiary will itself
change to Phoqus Pharmaceuticals (UK) Ltd.



Enquiries:


Phoqus Group plc Tel: 01732 870227
Dr Richard Mason, CEO
Dr Peter Johnson, CFO

Financial Dynamics Tel: 020 7831 3113
David Yates/John Gilbert

Nomura Code Securities Limited Tel: 020 7776 1200
Phil Walker



Notes to Editors


About Chronocort(TM)


Chronocort(TM) is the first circadian endocrine treatment for congenital adrenal
hyperplasia ("CAH") and adrenal insufficiency ("AI"). Chronocort(TM) uses
Phoqus' proprietary Qtrol(TM) modified release technology to provide a delayed-
and-sustained release profile of hydrocortisone to mimic the natural over-night
and early morning hormone levels found in healthy individuals that are
considered important in controlling both actual disease symptoms and also
reducing unwanted side effects resulting from excess steroid treatment.

Chronocort(TM) has successfully completed a number of phase I clinical studies
and planning is underway for the full clinical development programme which
includes pivotal pre-registration studies in both CAH patients and patients
suffering from AI.

Phoqus appointed a medical advisory board at the beginning of 2007 comprising
leading endocrinologists from Europe and the USA to assist the Company in the
design of the clinical development programmes able to demonstrate patient
benefits and clinical superiority of Chronocort(TM) over existing therapies for
both CAH and AI.

Some of the underlying intellectual property supporting the Chronocort(TM)
product is licensed from Diurnal Limited, a spin-out from the University of
Sheffield financed by Biofusion plc. Phoqus and Diurnal collaborate on certain
aspects of Chronocort(TM)'s development.




About Phoqus


Phoqus is a speciality pharmaceutical drug development company developing
secondary care products for patients with significant unmet medical needs
through the use of its proprietary drug delivery and re-formulation
technologies. These allow the company to change the pharmacokinetic profile of
drugs, either improving their therapeutic effect (efficacy and/or safety) in
existing indications, or to change their therapeutic effect so that they may
find use in new indications.

Phoqus' core capability is in oral drug delivery and it has combined its
technology platform with expertise in formulating tablets and tablet coat
powders to create a range of innovative and diverse drug delivery applications.
The Phoqus technology is protected by a substantial patent portfolio. Phoqus'
underlying technology platform is based upon electrostatic dry powder
deposition. This process deposits charged powder particles on to the surface of
a substrate with high precision.

Based in Kent, Phoqus was established in 1998 and was admitted to trading on AIM
in November 2005. It is listed under the symbol "PQS".

Further background on the Company can be found at www.phoqus.com.



                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
NOEEADPAAAPXEAE

Phoqus (LSE:PQS)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024

Phoqus (LSE:PQS)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024